Taro Pharmaceutical Industries (NYSE:TARO) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.

Several other equities research analysts also recently weighed in on TARO. Zacks Investment Research downgraded Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Thursday, August 16th. TheStreet raised Taro Pharmaceutical Industries from a “c+” rating to a “b-” rating in a report on Monday, June 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Taro Pharmaceutical Industries in a report on Friday, August 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $124.50.

Shares of TARO stock traded down $0.79 during trading hours on Monday, hitting $98.63. The stock had a trading volume of 19,000 shares, compared to its average volume of 65,627. The company has a market capitalization of $3.92 billion, a P/E ratio of 15.96 and a beta of 0.48. Taro Pharmaceutical Industries has a twelve month low of $93.01 and a twelve month high of $128.46.

Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings data on Thursday, August 9th. The company reported $1.71 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.33 by ($0.62). The firm had revenue of $154.62 million during the quarter, compared to analyst estimates of $179.54 million. Taro Pharmaceutical Industries had a net margin of 34.18% and a return on equity of 11.73%. equities research analysts expect that Taro Pharmaceutical Industries will post 7.65 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 1.6% during the second quarter. FMR LLC now owns 655,851 shares of the company’s stock worth $75,875,000 after purchasing an additional 10,562 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 9.8% during the second quarter. Renaissance Technologies LLC now owns 287,000 shares of the company’s stock worth $33,203,000 after purchasing an additional 25,600 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Taro Pharmaceutical Industries by 8.5% during the first quarter. Dimensional Fund Advisors LP now owns 260,672 shares of the company’s stock worth $25,739,000 after purchasing an additional 20,407 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 136.8% during the second quarter. Acadian Asset Management LLC now owns 235,930 shares of the company’s stock worth $27,295,000 after purchasing an additional 136,287 shares during the period. Finally, Freestone Capital Holdings LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 14.7% during the first quarter. Freestone Capital Holdings LLC now owns 166,748 shares of the company’s stock worth $16,464,000 after purchasing an additional 21,392 shares during the period. 10.40% of the stock is owned by institutional investors and hedge funds.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Featured Story: Google Finance Portfolio Workaround

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.